Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$23.00K$23.00Kderivedno prior Q4 2020 on file Net Income-$8.01M-$8.01MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$8,048,000N/M Operating Cash Flowderived-$5,052,000N/M Free Cash Flowderived-$5,052,000N/M Margins · derivedOperating margin-34991.3%
Net margin-34826.1%
ended Dec 31, 2021 · filed Mar 25, 2022 · 84 d after period end